Milsaperidone

DRUG2 trials

Sponsors

Vanda Pharmaceuticals Netherlands B.V., Vanda Pharmaceuticals

Conditions

Major Depressive DisorderMajor Depressive Disorder (MDD)

Phase 3

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

RecruitingNCT06830044

Vanda PharmaceuticalsMajor Depressive Disorder (MDD)

Start: 2025-03-03End: 2028-03-01Target: 500Updated: 2026-02-27

A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Milsaperidone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder

RecruitingCTIS2024-520333-68-00

Vanda Pharmaceuticals Netherlands B.V.Major Depressive Disorder

Start: 2025-09-26Target: 300Updated: 2025-09-10